Jr. Geisler et al., Ovarian cancer BRCA1 mutation detection: Protein truncation test (PTT) outperforms single strand conformation polymorphism analysis (SSCP), HUM MUTAT, 18(4), 2001, pp. 337-344
Recent studies have shown that the BRCA1 tumor suppressor gene plays a role
in the develops ment of both hereditary and sporadic ovarian cancer. Since
several different mechanisms may give rise to tumor gene defects, a better
understanding of these mechanisms may identify BRCA1 as an attractive ther
apeutic target in ovarian cancer. Sequencing this large gene is not practic
al on a population-wide basis. The optimal screening strategy is yet to be
determined. The purpose of our study is to compare two common screening tec
hniques: the protein truncation test (PTT) and single strand conformational
polymorphism analysis (SSCP). Ninety-four patients with epithelial ovarian
cancer and available snap-frozen tissue were screened for BRCA1 mutations
by both PTT (five individual PCR reactions with complete translation of the
product in the TNT System (Promega, Madison, WI)) and SSCP (41 individual
PCR reactions covering the entire coding sequence). All abnormal results we
re confirmed by sequencing. A paired peripheral blood DNA sample was utiliz
ed to determine if the sequence abnormality was a germline mutation. Twenty
, three mutations in BRCA1 were found in 22 patients (14 germline, eight so
matic, one unknown) including four novel mutations: E489X, 3558delT, 3871de
lGTCT, del exon 7-10. Although the predictive value of a negative test was
close for the two methods (PTT 99.1%, SSCP 99.8%), the comparison of positi
ve predictive value overwhelmingly favored PTT (100.0%, vs. 26.4%, respecti
vely). The specificity for PTT was 100.0% while the sensitivity was 82.6%.
While for SSCP, the specificity was 99.0% and the sensitivity was only 60.9
%. The concordance rate for the two screening tests was 88.9%. Only SSCP ca
n detect missense mutations. PTT is a superior screening test for truncatin
g BRCA1 mutations that are expected to be of clinical significance. Hum Mut
at 18:337-344, 2001. (C) 2001 Wiley-Liss, Inc.